サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1794458

生理用薬の世界市場

Menstrual Drugs

出版日
ページ情報
英文 290 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
生理用薬の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 290 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

生理用薬の世界市場は2030年までに124億米ドルに達する見込み

2024年に84億米ドルと推定される生理用薬の世界市場は、分析期間2024-2030年にCAGR 6.8%で成長し、2030年には124億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるホルモン治療薬は、CAGR 6.5%を記録し、分析期間終了時には48億米ドルに達すると予想されます。疼痛緩和薬セグメントの成長率は、分析期間中CAGR 7.8%と推定されます。

米国市場は23億米ドルと推定、中国はCAGR 10.6％で成長予測

米国の生理用薬市場は2024年に23億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR10.6％を引きずる形で、2030年までに26億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4％と6.6％と予測されています。欧州では、ドイツがCAGR 4.5%で成長すると予測されています。

世界の生理用薬市場- 主要動向と促進要因のまとめ

生理用薬が女性ヘルスケアで広く受け入れられている理由とは？

生理用薬は、月経の健康に対する世界の意識が高まり、月経にまつわる偏見が薄れつつある中、包括的な女性ヘルスケアに欠かせない要素として認識されつつあります。これらの薬剤は、月経困難症（生理痛）、月経痛（多量出血）、月経前症候群（PMS）、月経前不快気分障害（PMDD）など、月経に関連するさまざまな症状を管理するために設計されています。多くの女性にとって、これらの薬剤は痛みを軽減し、周期を調整し、気分の変動を安定させることで、生活の質を著しく向上させる。伝統的に、月経問題の治療はホルモン避妊薬か市販の鎮痛剤に限られていたが、より的を絞った医薬品の開発により、治療の幅が広がっています。非ステロイド性抗炎症薬（NSAIDs）、ホルモン療法、鎮痙薬、セロトニン再取り込み阻害薬などが現在では一般的に処方され、特定の症状に合わせた多様な解決策を提供しています。女性がリプロダクティブ・ヘルス（性と生殖に関する健康）の管理に積極的になるにつれ、生理用薬に対する需要は先進国、発展途上国を問わず高まっています。教育キャンペーン、ソーシャル・メディアでの認知度、ヘルスケア提供者のアドボカシーにより、月経をめぐる文化的な沈黙はさらに減少しています。政府やNGOもまた、公衆衛生の取り組みの一環として、特に学校保健プログラムや女性に焦点を当てたアウトリーチ活動において、月経管理を取り入れるようになってきています。このような努力の積み重ねにより、生理用薬はもはやオプションとはみなされず、女性の身体的、精神的、社会的幸福の中心であると認識される環境が整いつつあります。

医薬品イノベーションは、生理用薬の効果と安全性をどのように変えていますか？

医薬品の進歩は、生理用薬の有効性と安全性の両プロファイルを向上させ、患者の転帰を改善し、治療オプションに対する信頼性を高める上で重要な役割を果たしています。最も重要な開発のひとつは、ホルモンベースの治療法の進化であり、現在では、有効性を最大限に高めながら副作用を最小限に抑えるために、より低用量で、より的を絞ったデリバリーメカニズムで設計されています。周期延長経口避妊薬、ホルモン放出子宮内避妊具（IUD）、経皮吸収パッチは、慢性月経障害の女性に長期的な解決策を提供しています。これと並行して、消化管忍容性を改善した新世代の非ステロイド性抗炎症薬（NSAIDs）が、特に長期使用において、より安全に月経痛を管理するために導入されつつあります。バイオテクノロジーも月経の健康の革新に貢献しており、子宮内膜症やPMDDのような症状をよりよく理解し治療するために、遺伝子発現やホルモン調節を探求する研究が行われています。さらに、デジタル治療薬やアプリベースのプラットフォームが薬理学的解決策と組み合わされ始めており、女性が症状を追跡し、治療タイミングを最適化して最大限の効果を得られるよう支援しています。医薬品開発者は、月経の健康状態は遺伝、ライフスタイル、共存する健康状態によって大きく異なることを認識し、個別化医療へのアプローチにますます重点を置くようになっています。また、ホルモン剤を使用できない、あるいは使用したくない女性のために、非ホルモン療法を開発する取り組みも進められており、治療の包括性をさらに広げています。このような技術革新は、生理用薬の治療価値を向上させるだけでなく、特に青少年や初めて使用する人の間で、長期的な治療計画に以前は関連していたためらいや恐怖を軽減しています。

文化的規範や地域のヘルスケアアクセスは、生理用薬の導入にどのような影響を与えるのでしょうか？

文化的信条、ヘルスケア・インフラ、地域の認識レベルは、世界各地の生理用薬の採用に大きく影響します。ヘルスケアへのアクセスが比較的広く、女性の健康に関する会話がより普通に行われている先進諸国では、生理用薬の使用は、日常的な婦人科ケアと幅広い医薬品の利用によって支えられています。対照的に、多くの開発途上地域や低所得地域では、社会文化的タブー、宗教的制限、誤った情報が、女性が月経障害のために医療支援を求めることをいまだに妨げています。その結果、多くの女性が家庭療法に頼ったり、症状を黙って我慢したりして、診断や治療を遅らせています。しかし、擁護団体、国際保健機関、月経の非宗教化と月経の公平性の促進を目的とした教育キャンペーンなどの努力により、この動向は徐々に変わりつつあります。移動診療所、学校を拠点とした保健プログラム、遠隔医療プラットフォームは、農村部や十分なサービスを受けていない人々の生理用薬や情報へのアクセスを改善しています。経済的な要因も、女性が長期的な治療に専念できるかどうかに影響します。一部の国では、政府が生理用薬に補助金を出したり、必須医薬品リストに入れたりし始めており、これはより幅広い使用とプライマリー・ヘルスケア・サービスへの統合を促しています。さらに、学校のカリキュラムに月経に関する健康教育が盛り込まれたことで、若い女性たちが早期に医療機関に助けを求めるための知識と自信を身につけつつあります。このような社会力学の変化は、月経用医薬品市場を着実に再構築し、より包括的で地域の多様性やヘルスケア格差に対応したものにしています。

世界の生理用薬市場の成長を加速する主な促進要因は？

生理用薬市場の成長は、ヘルスケア政策、医薬品イノベーション、消費者行動、社会変化など、相互に関連するいくつかの動向によって牽引されています。第一に、PCOS、子宮内膜症、重症月経困難症などの月経障害の有病率の上昇が、効果的な医薬品介入に対する臨床需要を煽っています。第二に、先進国市場と新興国市場の両方でヘルスケアへのアクセスと保険適用が拡大し、月経治療がより手頃な価格で普及しつつあります。第三に、社会がよりオープンになり、月経の汚名が返上されたことで、より多くの女性が黙って苦しむのではなく、医学的解決策を求めるようになっています。第4に、非ホルモン剤や植物由来の薬剤の開発など、治療の選択肢が多様化したことで、ニーズや嗜好の異なる幅広い利用者が集まっています。第5に、デジタルヘルスプラットフォームの拡大により、遠隔地からの相談や個別化された治療計画が容易になり、女性が治療を開始・管理しやすくなっています。第6に、女性中心のブランドや健康団体が主導する的を絞ったマーケティング・キャンペーンや啓発活動が消費者を啓蒙し、製品の認知度を向上させています。第七に、公的機関と非公開会社の両方による女性の健康への投資の増加が、より安全で効果的な月経療法の研究開発を加速させています。最後に、世界のリプロダクティブ・ヘルスとウェルネスの課題に月経の健康が組み込まれたことで、長期的なヘルスケア計画における月経の重要性が確固たるものとなっています。これらの促進要因が相まって、月経用医薬品市場はより成熟し、弾力的なものとなっており、世界中の月経の健康管理に対する積極的かつ強力なアプローチを支えています。

セグメント

薬物タイプ（ホルモン治療薬、疼痛緩和薬、PMS・PMDD治療薬、月経調節薬、その他の薬物タイプ）、投与経路（経口投与、注射剤投与、局所投与）

調査対象企業の例

  • Abbott Laboratories
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Bayer AG
  • Cadila Healthcare（Zydus）
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • Gedeon Richter Plc.
  • Glenmark Pharmaceuticals
  • HRA Pharma（a Perrigo company）
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.（MSD）
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37367

Global Menstrual Drugs Market to Reach US$12.4 Billion by 2030

The global market for Menstrual Drugs estimated at US$8.4 Billion in the year 2024, is expected to reach US$12.4 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Hormonal Treatment Drugs, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Pain Relief Drugs segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 10.6% CAGR

The Menstrual Drugs market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Menstrual Drugs Market - Key Trends & Drivers Summarized

Why Are Menstrual Drugs Gaining Broader Acceptance in Women’s Healthcare?

Menstrual drugs are increasingly being recognized as essential components of comprehensive women’s healthcare, as global awareness about menstrual health rises and stigmas surrounding menstruation continue to erode. These medications are designed to manage a wide array of menstrual-related conditions such as dysmenorrhea (painful periods), menorrhagia (heavy bleeding), premenstrual syndrome (PMS), and premenstrual dysphoric disorder (PMDD). For many women, these drugs significantly improve quality of life by reducing pain, regulating cycles, and stabilizing mood fluctuations. Traditionally, the treatment of menstrual issues was limited to hormonal contraceptives or over-the-counter pain relievers, but the development of more targeted pharmaceutical options has expanded the therapeutic landscape. Non-steroidal anti-inflammatory drugs (NSAIDs), hormonal therapies, antispasmodics, and serotonin reuptake inhibitors are now commonly prescribed, offering diverse solutions tailored to specific symptoms. As women become more proactive about managing their reproductive health, the demand for menstrual drugs is growing across both developed and developing regions. Educational campaigns, social media awareness, and healthcare provider advocacy have further reduced the cultural silence surrounding menstruation. Governments and NGOs are also increasingly including menstrual management as part of public health initiatives, especially in school health programs and women-focused outreach. These collective efforts are creating an environment where menstrual drugs are no longer viewed as optional but are instead recognized as central to women's physical, emotional, and social well-being.

How Are Pharmaceutical Innovations Transforming the Effectiveness and Safety of Menstrual Drugs?

Pharmaceutical advancements are playing a critical role in enhancing both the effectiveness and safety profile of menstrual drugs, leading to better patient outcomes and greater confidence in treatment options. One of the most significant developments is the evolution of hormone-based therapies, which are now being engineered with lower doses and more targeted delivery mechanisms to minimize side effects while maximizing efficacy. Extended-cycle oral contraceptives, hormone-releasing intrauterine devices (IUDs), and transdermal patches are offering long-term solutions for women with chronic menstrual disorders. In parallel, newer generations of NSAIDs with improved gastrointestinal tolerability are being introduced to manage menstrual pain more safely, especially for long-term use. Biotechnology is also contributing to innovation in menstrual health, with research exploring gene expression and hormonal modulation to better understand and treat conditions like endometriosis and PMDD. Additionally, digital therapeutics and app-based platforms are beginning to be paired with pharmacological solutions, helping women track symptoms and optimize treatment timing for maximum benefit. Drug developers are increasingly focusing on personalized medicine approaches, recognizing that menstrual health varies widely based on genetics, lifestyle, and co-existing health conditions. Efforts are also underway to develop non-hormonal therapies for women who are unable or unwilling to use hormonal drugs, further broadening treatment inclusivity. These innovations are not only improving the therapeutic value of menstrual drugs but also reducing the hesitation or fear previously associated with long-term treatment plans, especially among adolescents and first-time users.

How Do Cultural Norms and Regional Healthcare Access Influence the Adoption of Menstrual Drugs?

Cultural beliefs, healthcare infrastructure, and regional awareness levels greatly influence the adoption of menstrual drugs across different parts of the world. In developed countries, where healthcare access is relatively widespread and conversations around women’s health are more normalized, the usage of menstrual drugs is supported by routine gynecological care and broad pharmaceutical availability. In contrast, in many developing and low-income regions, socio-cultural taboos, religious restrictions, and misinformation still hinder women from seeking medical assistance for menstrual disorders. As a result, many women rely on home remedies or endure symptoms in silence, delaying diagnosis and treatment. However, this trend is gradually changing, thanks to the efforts of advocacy groups, international health organizations, and educational campaigns aimed at destigmatizing menstruation and promoting menstrual equity. Mobile clinics, school-based health programs, and telemedicine platforms are improving rural and underserved populations’ access to menstrual drugs and information. Economic factors also play a role, as the affordability of drugs influences whether women can commit to long-term treatment. Governments in some countries are beginning to subsidize or include menstrual drugs in essential medicine lists, which is encouraging broader use and integration into primary healthcare services. Furthermore, the inclusion of menstrual health education in school curricula is equipping young women with the knowledge and confidence to seek medical help early. These shifting social dynamics are steadily reshaping the menstrual drug market, making it more inclusive and responsive to regional diversity and healthcare disparities.

What Are the Main Drivers Accelerating the Growth of the Global Menstrual Drugs Market?

The growth in the menstrual drugs market is driven by several interrelated trends across healthcare policy, pharmaceutical innovation, consumer behavior, and societal change. First, the rising prevalence of menstrual disorders such as PCOS, endometriosis, and severe dysmenorrhea is fueling clinical demand for effective pharmaceutical interventions. Second, increasing healthcare access and insurance coverage in both developed and emerging markets are making menstrual treatments more affordable and widespread. Third, greater societal openness and the destigmatization of menstruation are encouraging more women to seek medical solutions rather than suffer in silence. Fourth, the diversification of treatment options, including the development of non-hormonal and plant-based drugs, is attracting a wider range of users with different needs and preferences. Fifth, the expansion of digital health platforms is facilitating remote consultations and personalized treatment plans, making it easier for women to initiate and manage their care. Sixth, targeted marketing campaigns and awareness initiatives led by women-centric brands and health organizations are educating consumers and improving product visibility. Seventh, increased investment in women’s health by both public agencies and private pharmaceutical companies is accelerating research and development of safer, more effective menstrual therapies. Lastly, the integration of menstrual health into global reproductive health and wellness agendas is cementing its importance in long-term healthcare planning. Collectively, these drivers are contributing to a more mature and resilient menstrual drug market, one that supports a proactive and empowered approach to managing menstrual health around the world.

SCOPE OF STUDY:

The report analyzes the Menstrual Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs, Other Drug Types); Administration Route (Oral Administration, Injectable Administration, Topical Administration)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Abbott Laboratories
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Bayer AG
  • Cadila Healthcare (Zydus)
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • Gedeon Richter Plc.
  • Glenmark Pharmaceuticals
  • HRA Pharma (a Perrigo company)
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc. (MSD)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Menstrual Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Menstrual Health Throws the Spotlight on Therapeutic Solutions for Pain and Cycle Regulation
    • Increased Diagnosis of Conditions Like Endometriosis and PCOS Propels Growth in Hormonal and Anti-Inflammatory Drug Use
    • Growing Demand for Non-Opioid Pain Relief Expands the Addressable Market Opportunity for NSAIDs and Natural Alternatives
    • Shift Toward Over-the-Counter and Self-Care Solutions Strengthens the Business Case for Easily Accessible Menstrual Medications
    • Evolving Societal Attitudes Toward Menstrual Wellness Accelerate Demand for Targeted, Symptom-Specific Drugs
    • Product Innovation in Extended-Release and Combination Formulations Drives Adoption Among Younger Demographics
    • Rising Use of Oral Contraceptives for Menstrual Management Spurs Dual-Benefit Drug Utilization
    • Telehealth and DTC Women's Health Platforms Throw the Spotlight on Digital Access to Menstrual Prescriptions
    • Increased Focus on Quality of Life and Workplace Productivity Supports Greater Use of Period Pain Medications
    • Demand for Plant-Based and Hormone-Free Menstrual Relief Products Drives Growth in Complementary Therapies
    • Clinical Interest in Personalized Medicine and Hormone Profiling Expands Potential for Tailored Menstrual Drug Regimens
    • Menstrual Tracking Apps and Digital Health Tools Generate Insights That Spur Demand for Proactive Pharmaceutical Interventions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Menstrual Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Menstrual Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hormonal Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hormonal Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hormonal Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Pain Relief Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Pain Relief Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Pain Relief Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for PMS & PMDD Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for PMS & PMDD Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for PMS & PMDD Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Menstrual Regulation Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Menstrual Regulation Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Menstrual Regulation Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • JAPAN
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • CHINA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • EUROPE
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Menstrual Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • FRANCE
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • GERMANY
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Menstrual Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • INDIA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Menstrual Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Menstrual Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • AFRICA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030

IV. COMPETITION